DOP2018000034A - Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas - Google Patents
Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismasInfo
- Publication number
- DOP2018000034A DOP2018000034A DO2018000034A DO2018000034A DOP2018000034A DO P2018000034 A DOP2018000034 A DO P2018000034A DO 2018000034 A DO2018000034 A DO 2018000034A DO 2018000034 A DO2018000034 A DO 2018000034A DO P2018000034 A DOP2018000034 A DO P2018000034A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- combinations
- antibody
- same
- modulator
- tlr4 modulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen en este documento combinaciones de un modulador de OX40 y un modulador de TLR4, sus composiciones farmacéuticas, sus usos y métodos de tratamiento que comprenden administrar dicha combinación, incluyendo sus usos en el cáncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562201828P | 2015-08-06 | 2015-08-06 | |
US201562247488P | 2015-10-28 | 2015-10-28 | |
US201662300400P | 2016-02-26 | 2016-02-26 | |
US201662322906P | 2016-04-15 | 2016-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2018000034A true DOP2018000034A (es) | 2018-10-31 |
Family
ID=56131579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2018000034A DOP2018000034A (es) | 2015-08-06 | 2018-02-05 | Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas |
Country Status (21)
Country | Link |
---|---|
US (2) | US20170275371A1 (es) |
EP (1) | EP3331560A1 (es) |
JP (2) | JP2018525378A (es) |
KR (1) | KR20180032641A (es) |
CN (1) | CN108025073A (es) |
AU (1) | AU2016304401B2 (es) |
BR (1) | BR112018002530A2 (es) |
CA (1) | CA2994910A1 (es) |
CL (1) | CL2018000303A1 (es) |
CO (1) | CO2018001238A2 (es) |
CR (1) | CR20180080A (es) |
DO (1) | DOP2018000034A (es) |
EA (1) | EA201890457A1 (es) |
HK (1) | HK1249410A1 (es) |
IL (1) | IL257067A (es) |
MA (1) | MA43556A (es) |
MX (1) | MX2018001515A (es) |
PH (1) | PH12018500254A1 (es) |
TW (1) | TW201716084A (es) |
WO (1) | WO2017021791A1 (es) |
ZA (1) | ZA201800468B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106132439A (zh) | 2014-03-31 | 2016-11-16 | 豪夫迈·罗氏有限公司 | 包含抗血管发生剂和ox40结合激动剂的组合疗法 |
EP3484518A4 (en) | 2016-07-07 | 2020-04-22 | The Board of Trustees of the Leland Stanford Junior University | ANTIBODY ADJUVANT CONJUGATES |
WO2019133647A1 (en) * | 2017-12-29 | 2019-07-04 | Thevax Genetics Vaccine Co., Ltd. | Combination of a fusion protein vaccine with anti-ox40 antibody for use in eliciting antigen-specific immune responses |
WO2020030570A1 (en) * | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
WO2020228828A1 (zh) * | 2019-05-15 | 2020-11-19 | 郑州威瑞生物技术有限公司 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
AU2021380287A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | Novel aminoalkyl glucosaminide 4-phosphate derivative |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
MXPA02011486A (es) | 2000-05-19 | 2004-01-26 | Corixa Corp | Tratamiento profilactico y terapeutico de enfermedades infecciosas, autoinmunes y alergicas con compuestos a base de mono y disacarido. |
EP1311522B1 (en) | 2000-08-04 | 2006-03-22 | Corixa Corporation | New immunoeffector compounds |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
EP2572715A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
NZ629913A (en) | 2010-08-23 | 2016-01-29 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
CN103946238B (zh) * | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
EP2659906A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
US20150190506A1 (en) * | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
-
2016
- 2016-05-30 TW TW105116887A patent/TW201716084A/zh unknown
- 2016-06-03 MX MX2018001515A patent/MX2018001515A/es unknown
- 2016-06-03 WO PCT/IB2016/053285 patent/WO2017021791A1/en active Application Filing
- 2016-06-03 EP EP16729378.6A patent/EP3331560A1/en not_active Withdrawn
- 2016-06-03 MA MA043556A patent/MA43556A/fr unknown
- 2016-06-03 CN CN201680054466.7A patent/CN108025073A/zh active Pending
- 2016-06-03 AU AU2016304401A patent/AU2016304401B2/en not_active Ceased
- 2016-06-03 CA CA2994910A patent/CA2994910A1/en not_active Abandoned
- 2016-06-03 BR BR112018002530A patent/BR112018002530A2/pt not_active Application Discontinuation
- 2016-06-03 EA EA201890457A patent/EA201890457A1/ru unknown
- 2016-06-03 JP JP2018506136A patent/JP2018525378A/ja active Pending
- 2016-06-03 CR CR20180080A patent/CR20180080A/es unknown
- 2016-06-03 KR KR1020187005697A patent/KR20180032641A/ko unknown
-
2017
- 2017-06-06 US US15/615,032 patent/US20170275371A1/en not_active Abandoned
-
2018
- 2018-01-22 IL IL257067A patent/IL257067A/en unknown
- 2018-01-23 ZA ZA2018/00468A patent/ZA201800468B/en unknown
- 2018-02-02 PH PH12018500254A patent/PH12018500254A1/en unknown
- 2018-02-02 CL CL2018000303A patent/CL2018000303A1/es unknown
- 2018-02-05 DO DO2018000034A patent/DOP2018000034A/es unknown
- 2018-02-06 CO CONC2018/0001238A patent/CO2018001238A2/es unknown
- 2018-06-22 HK HK18108033.2A patent/HK1249410A1/zh unknown
-
2019
- 2019-06-28 US US16/455,957 patent/US20190338042A1/en not_active Abandoned
-
2021
- 2021-05-21 JP JP2021086434A patent/JP2021121622A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20180080A (es) | 2018-04-02 |
CO2018001238A2 (es) | 2018-05-10 |
HK1249410A1 (zh) | 2018-11-02 |
AU2016304401A1 (en) | 2018-02-15 |
US20190338042A1 (en) | 2019-11-07 |
JP2021121622A (ja) | 2021-08-26 |
EA201890457A1 (ru) | 2018-09-28 |
ZA201800468B (en) | 2019-07-31 |
WO2017021791A1 (en) | 2017-02-09 |
BR112018002530A2 (pt) | 2018-09-25 |
PH12018500254A1 (en) | 2018-08-13 |
KR20180032641A (ko) | 2018-03-30 |
AU2016304401B2 (en) | 2019-05-16 |
CL2018000303A1 (es) | 2018-07-06 |
EP3331560A1 (en) | 2018-06-13 |
MX2018001515A (es) | 2018-03-15 |
MA43556A (fr) | 2021-03-24 |
IL257067A (en) | 2018-03-29 |
US20170275371A1 (en) | 2017-09-28 |
CA2994910A1 (en) | 2017-02-09 |
TW201716084A (zh) | 2017-05-16 |
CN108025073A (zh) | 2018-05-11 |
JP2018525378A (ja) | 2018-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2018000034A (es) | Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CL2016003056A1 (es) | Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer. | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
AR106582A1 (es) | Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos | |
GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
CL2016002971A1 (es) | Combinación. | |
CL2016003260A1 (es) | Profármacos de gemcitabina | |
CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
CO2017002472A2 (es) | Formulación de acetato de abiraterona | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
DOP2017000260A (es) | Piroglutamato de vortioxetina | |
BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CY1121105T1 (el) | Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv | |
UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
CO2017002356A2 (es) | Métodos para tratar la depresión usando moduladores de nmda | |
CO2018008249A2 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b | |
BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe |